May-13-22 11:52AM |
Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool |
May-09-22 08:47AM |
10 Biggest Price Target Changes For MondayBenzinga |
May-06-22 03:02AM |
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues BeatZacks Investment Research |
May-05-22 08:55AM |
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research |
08:43AM |
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder StudyBenzinga |
May-04-22 03:19AM |
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & MoreZacks Investment Research |
May-02-22 07:30AM |
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering ConferenceGlobeNewswire Inc. |
Apr-28-22 10:09AM |
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga |
09:15AM |
4 Analysts Have This to Say About Intellia TherapeuticsBenzinga |
Apr-28-22 07:30AM |
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company UpdatesGlobeNewswire Inc. |
Apr-20-22 07:40AM |
3 Top Biotech Stocks Ready for a Bull RunThe Motley Fool |
Apr-19-22 06:20AM |
3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool |
Apr-13-22 10:45AM |
CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool |
Apr-11-22 10:12AM |
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?Zacks Investment Research |
Mar-17-22 09:36AM |
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research |
Mar-16-22 12:27PM |
Who Benefits From Amazon's Stock Split?The Motley Fool |
Mar-11-22 12:23PM |
Intellia (NTLA) Depreciates 27% Over a Month: Here's WhyZacks Investment Research |
Mar-10-22 10:11AM |
Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AMLZacks Investment Research |
Mar-09-22 04:01AM |
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia GlobeNewswire Inc. |
Mar-07-22 10:03AM |
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022Benzinga |
Mar-03-22 01:21AM |
This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch |
06:29AM |
Is Intellia a Good Gene-Editing Stock to Buy Now?The Motley Fool |
Mar-03-22 06:15AM |
Can Biotech Stocks Provide Crypto-Like Growth for Your Portfolio?The Motley Fool |
Mar-02-22 07:24AM |
This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch |
Mar-01-22 11:05AM |
Analyst Ratings For Intellia TherapeuticsBenzinga |
07:51AM |
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent ResolutionBenzinga |
Mar-01-22 07:30AM |
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid LeukemiaGlobeNewswire Inc. |
06:49AM |
This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch |
Feb-28-22 04:01AM |
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinGlobeNewswire Inc. |
02:56AM |
This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch |
Feb-28-22 10:09AM |
This new competitor to the ARK Innovation ETF focuses on disruptive companies but aims to reduce volatilityMarketWatch |
Feb-25-22 09:45AM |
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/YZacks Investment Research |
Feb-24-22 07:30AM |
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc. |
Feb-21-22 06:20AM |
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?Zacks Investment Research |
Feb-18-22 10:06AM |
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022Benzinga |
Feb-17-22 03:14AM |
How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?Benzinga |
03:02AM |
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to DeclineZacks Investment Research |
Feb-17-22 07:30AM |
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022GlobeNewswire Inc. |
Feb-16-22 11:50AM |
Intellia (NTLA) Up on Deal With ONK for Cancer TherapiesZacks Investment Research |
10:35AM |
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?Zacks Investment Research |
Feb-15-22 07:30AM |
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with CancerGlobeNewswire Inc. |
Feb-14-22 10:27AM |
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022Benzinga |
Feb-03-22 07:30AM |
Intellia Therapeutics Announces Acquisition of Rewrite TherapeuticsGlobeNewswire Inc. |
Jan-29-22 04:25AM |
A Deep Dive Into the Video Game IndustryThe Motley Fool |
10:30AM |
3 Growth ETFs to Consider Buying During This CorrectionThe Motley Fool |
Jan-22-22 12:35PM |
Q&A With ARK Invest's Cathie WoodSeeking Alpha |
Jan-19-22 10:46AM |
Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugZacks Investment Research |
06:03AM |
5 Charts to Remember if the Stock Market Crashes in 2022The Motley Fool |
Jan-16-22 06:47AM |
Is Beam Therapeutics a Good Stock to Buy Now?The Motley Fool |
Jan-07-22 02:00AM |
"Motley Fool Money" 2022 Investing PreviewThe Motley Fool |